FDG- and amyloid-PET in Alzheimer's disease: Is the whole greater than the sum of the parts?

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 3, 2011, Pages 250-264

  Mosconi, L ^a   McHugh, P F ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzherimer disease; Cell aging; Positron emission tomography

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; FLUORODEOXYGLUCOSE F 18;

AGING; ALZHEIMER DISEASE; DEMENTIA; EARLY DIAGNOSIS; FAMILY HISTORY; GENE MUTATION; GENOTYPE; HUMAN; IN VIVO STUDY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW;

AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BRAIN; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS;

EID: 79961001534     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
2. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD et al. Dementia and Alzheimer disease incidence: A prospective cohort study. Arch Neurol 2002; 59:1737-46.
3. Brookmeyer R, Johnson E, Ziegler-Graha K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzh Dementia 2007;3:186-91. (Pubitemid 46825511)
4. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. State-specific projections through 2025 of alzheimer disease prevalence. Neurology 2004;62:1645. (Pubitemid 38608220)
5. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560-74.
6. Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to alzheimer disease. Arch Neurology 2009;66:1254-9.
7. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brown-lee LM et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86.
8. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22.
9. Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathologica 1996;92:197-201. (Pubitemid 26248463)
10. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999;52:1158-65.
11. Morris JC, Storandt M, McKeel DW, Rubin EH, Price JL, Grant EA et al. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheiemer's disease. Neurology 1996;46:707-19.
12. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991;82:239-59.
13. Selkoe DJ. Alzheimer's disease: genotypes, phenotype, and treatments. Science 1997;275:630-1. (Pubitemid 27061322)
14. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95:6448-53.
15. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999;155:853-62.
16. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992;42:1681-8.
17. Giannakopoulos P, Hof PR, Mottier S, Michel JP, Bouras C. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital:retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathologica 1994;87:456-68. (Pubitemid 24128973)
18. Ulrich J. Alzheimer changes in nondemented patients younger than sixty-five:Possible early stages of Alzheimer's disease and senile dementia of Alzheimer type. Ann Neurol 1985;17:273-7. (Pubitemid 15136602)
19. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science 1997;278:412-9. (Pubitemid 27454417)
20. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease.cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168-70. (Pubitemid 14029099)
21. Mosconi L, Berti V, Swerdlow RH, Pupi A, Duara R, de Leon MJ. Maternal transmission of Alzheimer's disease:Prodromal metabolic phenotype and the search for genes. Human Genomics 2010;4:170-93.
22. Ono M, Wilson A, Nobrega J, Westaway D, Verhoeff P, Zhuang ZP et al. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol 2003;30:565-71. (Pubitemid 37289318)
23. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A et al. Binding characteristics of radiofluorinated 6-dialkylamino-2- naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001;21:1-5.
24. Rowe CC, Ackermann U, Browne W, Mulligan R, Pike KL, O'Keefe G et al. Imaging of amyloid beta in Alzheimer's disease with (18)F-BAY94-9172, a novel PET tracer:proof of mechanism. Lancet Neurol 2008;7:129-35.
25. Klunk WE, Engler H, Nordberg A, Yanming W, Blomqvist G, Holt DP et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19. (Pubitemid 38269583)
26. Prohovnik I, Perl DP, Davis KL, Libow L, Lesser G, Haroutunian V. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology 2006;66:49-55.
27. Neve RL, Robakis NK. Alzheimer's diseases re-examination of the amyloid hypothesis. Trends Neurosci 1998;21:15-9. (Pubitemid 128766369)
28. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000;283:1571-7.
29. Dowling NM, Tomaszewski FS, Reed BR, Sonnen JA, Strauss JA, Strauss ME et al. Neuropathological Associates of Multiple Cognitive Functions in Two Community-Based Cohorts of Older Adults. J Int Neuropsychol Soc 2010 [In press].
30. Shulman JM, Chibnik LB, Aubin C, Schneider JA, Bennett DA, De Jager PL. Intermediate phenotypes identify divergent pathways to Alzheimer's disease. PLoS One 2010;5:11244.
31. Duara R, Loewenstein DA, Greig M, Acevedo A, Potter E, Appel J et al. Reliability and validity of an algorithm for the diagnosis of normal cognition, mild cognitive impairment, and dementia:implications for multicenter research studies. Am J Geriatr Psychiatry 2010;18:363-70.
32. Kamat SM, Kamat AS, Grossberg GT. Dementia risk prediction: are we there yet? Clin Geriatr Med 2010;26:113-23.
33. Mazziotta JC, Phelps ME. Positron Emission Tomography studies of the brain. In:Phelps ME, Mazziotta JC, Schelbert H, editors. Positron Emission Tomography & Autoradiography:Principles & Applications for the Brain & Heart. New York: Raven Press; 1986:493-579.
34. Silverman DHS, Small GW, Chang CY, Lu CS, Kung de Aburto MA, Chen W et al. Positron emission tomography in evaluation of dementia:Regional brain metabolism and long-term outcome. JAMA 2001;286:2120-7. (Pubitemid 34041597)
35. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94. (Pubitemid 27304784)
36. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. Eur J Nucl Med 2005;32:486-510.
37. Kim EJ, Cho SS, Jeong Y, Park KC, Kang SJ, Kang E et al. Glucose metabolism in early onset versus late onset Alzheimer's disease:an SPM analysis of 120 patients. Brain 2005;128:1790-801.
38. Blass JP. Alzheimer's disease and Alzheimer's dementia:distinct but overlapping entities. Neurobiol Aging 2002;23:1077-84. (Pubitemid 35447790)
39. Grady CL, Haxby JV, Schlageter NL, Berg G, Rapoport SI. Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type. Neurology 1986;36:1390-2.
40. Brown AM, Sheu RK, Mohs R, Haraoutunian V, Blass JP. Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA). J Mol Neurosci 2001;16:41-8. (Pubitemid 32402344)
41. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-16.
42. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G et al. Multi-center standardized FDG-PET diagnosis of Mild Cognitive Impairment, Alzheimer's disease and other dementias. J Nucl Med 2008;49:390-8. (Pubitemid 351355204)
43. Szelies B, Mielke R, Herholz K, Heiss W-D. Quantitative topographical EEG compared to FDG PET for classification of vascular and degenerative dementia. Electroencephalog Clin Neurophysiol 1994;91:131-9. (Pubitemid 24246467)
44. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G et al. Imaging {beta}-amyloid burden in aging and dementia. Neurology 2007;68:1718-25. (Pubitemid 46763260)
45. Kemppainen N, Aalto S, Wilson I, Nagren K, Helin S, Bruck A et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006;67:1575-80.
46. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P et al. Beta-amyloid imaging and memory in non-demented individuals:evidence for preclinical Alzheimer's disease. Brain 2007;130:2837-44. (Pubitemid 350033975)
47. Mintun MAM, LaRossa GN, Sheline YIM, Dence CSM, Lee SYP, Mach RHP et al. [11C]PIB in a nondemented population:Potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-52.
48. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007;68:1603-6.
49. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, De Santi S et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment and Alzheimer's disease. Eur J Nucl Med Molec Imaging 2008;35:2169-81.
50. Jack CR, Jr., Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-80.
51. Johansson A, Savitcheva I, Forsberg A, Engler H, Langstrom B, Nordberg A et al. [(11)C]-PIB imaging in patients with Parkinson's disease:preliminary results. Parkins Relat Disord 2008;14:345-7.
52. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229-34. (Pubitemid 47525398)
53. Mathis CA, Wang Y, Klunk W. Imaging [beta]-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain. Current Pharmaceutical Design 2004;10:1469-92.
54. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L et al. PIB is a non-specific imaging marker of amyloid-beta (A{beta}) peptide-related cerebral amyloidosis. Brain 2007;130:2607-15. (Pubitemid 47511709)
55. Jagust WJ. Mapping brain beta-amyloid. Curr Opin Neurol 2009;22:356-61.
56. Mesulam MM. Neuroplasticity failure in Alzheimer's disease:bridging the gap between plaques and tangles. Neuron 1999;24:521-9.
57. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856-66. (Pubitemid 44684508)
58. Jack CR, Jr., Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-80.
59. Klunk WE, Mathis CA, Price JC, Lopresti BJ, DeKosky ST. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2805-7. (Pubitemid 44684503)
60. Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;8:119-28.
61. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ et al. PET of brain amyloid and tau in mild cognitive impairment. New Engl J Med 2006;355:2652-63. (Pubitemid 44969124)
62. de Leon MJ, Convit A, Wolf OT, Tarshish CY, De Santi S, Rusinek H et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966-71. (Pubitemid 32878727)
63. Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 2008;29:676-92.
64. Jagust WJ, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol 2006;59:673-81.
65. Mosconi L, Mistur R, Switalski R, Tsui W, Glodzik L, Li Y et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Molec Imaging 2009;36:811-22.
66. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66:1469-75.
67. Jobst KA, Barnetson LPD, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: The use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT and Apo E4 in medial temporal lobe dementia. Int Psychogeriat 1998;10:271-302. (Pubitemid 28470188)
68. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001;32:181-4. (Pubitemid 33030187)
69. Kennedy AM, Newman SK, Frackowiak RS, Cunningham VJ, Roques P, Stevens J et al. Chromosome 14 linked familial Alzheimer's disease. A clinico-pathological study of a single pedigree. Brain 1995;118:185-205.
70. Perani D, Grassi F, Sorbi S, Nacmias B, Piacentini S, Piersanti P et al. PET study in subjects from two Italian FAD families with APP717 Val to llue mutation. Eur J Neurol 1997;4:214-20. (Pubitemid 27343191)
71. Kennedy AM, Frackowiak RSJ, Newman SK, Bloomfield PM, Seaward J, Roques P et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's Disease. Neurosci Lett 1995;186:17-20.
72. Mosconi L, Sorbi S, de Leon MJ, Li Y, Nacmias B, Bessi V et al. Hypometabolism exceeds atrophy in presymptomatic early-onset Familial Alzheimer's disease. J Nucl Med 2006;47:1778-86.
73. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27:6174-84. (Pubitemid 46890033)
74. Koivunen J, Verkkoniemi S, Aalto S, Paetau A, Ahonen JP, Viitanen M et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 2008;131:1845-53.
75. Remes AM, Laru L, Tuominen H, Aalto S, Kemppainen N, Mononen H et al. Carbon 11-Labeled Pittsburgh Compound B Positron Emission Tomographic Amyloid Imaging in Patients With APP Locus Duplication. Arch Neurol 2008;65:540-4.
76. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment:clinical characterization and outcome. Arch Neurol 1999;56:303-8. (Pubitemid 29120227)
77. Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment:Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374-7.
78. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V et al. MCI conversion to dementia and the APOE genotype:a prediction study with FDG-PET. Neurology 2004;63:2332-40. (Pubitemid 40024346)
79. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease:a PET follow-up study. Eur J Nucl Med Molec Imaging 2003;30:1104-113. (Pubitemid 36988222)
80. Silverman DHS, Truong CT, Kim SK, Chang CY, Chen W, Kowell AP et al. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation:comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab 2003;80:350-5.
81. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cog Dis 1999;10:494-504.
82. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P et al. Prediction of individual outcome in MCI by means of genetic assessment and 18F-FDG PET. J Nucl Med 2005;46:1625-32. (Pubitemid 46211586)
83. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B et al. Heterogeneity of brain glucose metaboism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005;62:1728-33. (Pubitemid 41626670)
84. Lowe VJ, Kemp BJ, Jack CR, Jr., Senjem M, Weigand S, Shiung M et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009;50:878-86.
85. Forsberg A, Engler H, Almkvist O, Blomqvist G, Hagman G, Wall A et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-65.
86. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K et al. Conversion of amyloid positive and negative MCI to AD over 3 years. An 11C-PIB PET study. Neurology 2009;73:754-60.
87. Wolk DA, Price JC, Saxton JA, snitz BE, James JA, Lopez OL et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009;65:557-68.
88. Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease:possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 2003;84:1215-36.
89. Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942-7.
90. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. New Engl J Med 1996;334:752-8. (Pubitemid 26089356)
91. Small GW, Ercoli LM, Silverman DHS, Huang SC, Komo S, Bookheimer S et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:6037-42. (Pubitemid 30367519)
92. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotesA foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:3334-9. (Pubitemid 32220846)
93. Reiman EM, Chen K, Alexander GE, Caselli RJ Bandy D, Osborne D et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 2004;101:284-9.
94. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009;106:6820-5.
95. Cupples LA, Farrer LA, Sadovnik AD, Relkin N, Whitehouse P, Green P. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease:The REVEAL study. Genet Med 2004;6:192-6. (Pubitemid 39005858)
96. Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002;287:329-36.
97. Silverman JM, Ciresi G, Smith CJ, Marin DB, Schnaider-Beeri M. Variability of familial risk of Alzheimer disease across the late life span. Arch Gen Psychiat 2005;62:565-73. (Pubitemid 40628886)
98. Mosconi L, Brys M, Switalski R, Mistur R, Glodzik-Sobanska L, Pirraglia E et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA 2007;104:19067-72.
99. Mosconi L, Mistur R, Glodzik L, Brys M, Switalski R, Pirraglia E et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer's. Neurology 2009;72:513-20.
100. Mosconi L, Rinne JO, Tsui W, Berti V, Li Y, Murray J et al. Increased fibrillar amyloid-β burden in normal individuals with a family history of late-onset Alzheimer's disease. Proc Natl Acad Sci USA 2010;107:5949-54.
101. Honea RA, Swerdlow RH, Vidoni E, Goodwin J, Burns JM. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 2009;74:113-20.
102. Andrawis JP, Hwang KS, Green AE, Kotlerman J, Elashoff D, Morra JH et al. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging 2010 [In press].
103. Bendlin BB, Ries ML, Canu E, Sodhi A, Lazar M, Alexander AL et al. White matter is altered with parental family history of Alzheimer's disease. Alzheimers Dement 2010;6:394-403.
104. Crystal HA, Dickson D, Davies P, Masur D, Grober E, Lipton RB. The relative frequency of "dementia of unknown etiology" increases with age and is nearly 50% in nonogenerians. Arch Neurol 2000;57:713-9.
105. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M et al. Clinico-pathologic studies in dementia:nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988;38:1682-7. (Pubitemid 18265029)
106. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-92. (Pubitemid 33143977)
107. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 2001;58:1395-402. (Pubitemid 32845990)
108. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al. Physical basis of cognitive alterations in Alzheimer's disease:Synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-80.
109. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in alzheimer's disease treatment studies. Am J Psychiatry 2002;159:738-45. (Pubitemid 34465046)
110. Shoghi-Jadid K, Barrio JR, Kepe V, Huang SC. Exploring a mathematical model for the kinetics of beta-amyloid molecular imaging probes through a critical analysis of plaque pathology. Mol Imaging Biol 2006;8:151-62. (Pubitemid 44193391)
111. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-40. (Pubitemid 26292051)
112. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528-47. (Pubitemid 41541962)
113. 113- Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X et al. Simplified quantification of Pittsburgh compound B amyloid Imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959-72. (Pubitemid 46657441)
114. Shoghi-Jadid K, Barrio JR, Kepe V, Wu HM, Small GW, Phelps ME et al. Imaging beta-amyloid fibrils in Alzheimer's diseases critical analysis through simulation of amyloid fibril polymerization. Nucl Med Biol 2009;32:337-51. (Pubitemid 40692684)
115. Powell MR, Smith GE, Knopman DS, Parisi JE, Boeve BF, Petersen RC et al. Cognitive Measures Predict Pathologic Alzheimer Disease. Arch Neurol 2006;63:865-8.
116. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald B, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985;82:4245-9.
117. Isacson O, Seo H, Lin L, Albeck D, Granholm AC. Alzheimer's disease and Down's syndrome:roles of APP, trophic factors and ACh. Trends Neurosci 2002;25:79-84. (Pubitemid 34123299)
118. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358-68.
119. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease:prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 1988;38:1688-93. (Pubitemid 18265030)
120. Silverman DHS, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia. sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. Clin Positron Imaging 1999;2:119-30.